Skip to content
Koha Jone Logo
  • Latest
  • News
  • Trending
  • WebTV
  • Region
  • World
  • Politics
  • Kosovo
  • Economy
  • Showbiz
  • Sports
  • Shqip
  • English
Read in app
  • Shqip
  • English
  • Latest
  • News
  • Trending
  • WebTV
  • Region
  • World
  • Politics
  • Kosovo
  • Economy
  • Showbiz
  • Sports
  • News
  • Trending
  • Politics
  • Forum
  • WebTV
  • Editorial
  • Kosovo
  • Region
  • World
  • Sports
  • Economy
  • Showbiz
  • Culture
  • Health
  • Technology
  • Interview
  • Chronicle
  • Tourism
  • Social
  • History
Latest news

Newspaper "KOHA JONË" founded as an independent publication on 11 May 1991
Publisher: Nikoll LESI. Editorial office address: Rruga "Sami Frasheri", Pallatet e Aviacionit të Vjetër Nr. 2, TIRANA - ALBANIA

Site by

View options

Preview Sunday, 22 November 2026, 18:23 𝐏𝐈𝐊𝐈𝐀𝐓𝐀 𝐄 𝐄𝐔𝐑𝐎𝐒 𝐃𝐇𝐄 𝐒𝐀𝐌𝐈𝐓𝐈 𝐈 𝐀𝐑𝐔𝐁𝐄̈𝐒 𝐄𝐍𝐃𝐄 𝐕𝐈𝐉𝐎𝐍! Nga Ilir Meta- Duke e uruar lekun që po ia ul kokën euros, që ka ndryshuar prefiksin dhe ka zbritur në 89 lekë, është…
Black and white preview
Text size
  • Trending
  • Qafë Thanë
  • Erion Veliaj
  • Messi
  • Robbery in Durrës
  • Xhensila Myrtezaj
  • Accident in Fier
  • Spiropali
  • Vučić
Latest news
Trending
  • Qafë Thanë
  • Erion Veliaj
  • Messi
  • Robbery in Durrës
  • Xhensila Myrtezaj
  • Accident in Fier
  • Spiropali
  • Vučić
KOHA JONË Latest news, always with you
Install

New vaccine against pancreatic cancer shows promising results, 99% of patients develop an immune response

Trending Monday, 2 November 2026 14:12
New vaccine against pancreatic cancer shows promising results, 99% of patients develop an immune response
Add to preferred sources

Share

Facebook WhatsApp Email X

A new vaccine against pancreatic cancer, one of the most lethal forms of the disease, has shown promising results in a clinical trial, triggering an immune response in 99% of the vaccinated patients who were evaluated.

The vaccine, called cam upepimut (cam upepimut), was developed by the company Elicio Therapeutics. It aims to train the T cells of the immune system to recognize and attack seven of the most common mutations of the KRAS gene, which are linked to the development of most cases of pancreatic cancer.

The phase two study, led by specialists from the Mayo Clinic, included 144 patients who had previously undergone surgery and chemotherapy. They were randomly divided into two groups, one of which received the vaccine and the other did not.

You might be interested in

BepiColombo enters Mercury orbit after eight-year journey

BepiColombo enters Mercury orbit after eight-year journey

1 hour ago
German army in Lithuania tests kamikaze drones and AI targeting

German army in Lithuania tests kamikaze drones and AI targeting

1 hour ago
Joint border crossing point opens at Qafë Thanë

Joint border crossing point opens at Qafë Thanë

3 hours ago
Advertisement Complaint in Koha Jonë
Advertisement Complaint in Koha Jonë

Of the 90 vaccinated patients, the immune response was assessed in 89 of them. The results showed that these patients developed T cells that recognized the mutations of the KRAS gene. In more than 80% of cases, the immune response was more than nine times stronger than before.

AdvertisementSwiss DigitalComplaint in Koha Jonë

Also, patients who developed the strongest immune response tend to stay longer without signs of the cancer returning.

Researchers are planning a larger phase three study, which will also test booster doses of the vaccine and its combination with other treatments.

However, the vaccine is still in the clinical trial stage, and further research is needed to confirm its effectiveness.

The study was published in the scientific journal Nature Medicine (2026).

Related tags

cancerpancreasvaccine
Add to preferred sources

Share

Facebook WhatsApp Email X

Latest

𝐏𝐈𝐊𝐈𝐀𝐓𝐀 𝐄 𝐄𝐔𝐑𝐎𝐒 𝐃𝐇𝐄 𝐒𝐀𝐌𝐈𝐓𝐈 𝐈 𝐀𝐑𝐔𝐁𝐄̈𝐒 𝐄𝐍𝐃𝐄 𝐕𝐈𝐉𝐎𝐍!
3 minutes ago

𝐏𝐈𝐊𝐈𝐀𝐓𝐀 𝐄 𝐄𝐔𝐑𝐎𝐒 𝐃𝐇𝐄 𝐒𝐀𝐌𝐈𝐓𝐈 𝐈 𝐀𝐑𝐔𝐁𝐄̈𝐒 𝐄𝐍𝐃𝐄 𝐕𝐈𝐉𝐎𝐍!

Barcelona come from behind to beat Villarreal 3-2 with three goals in 10 minutes
25 minutes ago

Barcelona come from behind to beat Villarreal 3-2 with three goals in 10 minutes

BepiColombo enters Mercury orbit after eight-year journey
1 hour ago

BepiColombo enters Mercury orbit after eight-year journey

German army in Lithuania tests kamikaze drones and AI targeting
1 hour ago

German army in Lithuania tests kamikaze drones and AI targeting

Most read

1 Elisa Spiropali: I am the one who blows the wind, brings the rain, sends the hail, raises the tsunami, dries up the seas, flattens the mountains…
6 hours ago

Elisa Spiropali: I am the one who blows the wind, brings the rain, sends the hail, raises the tsunami,...

2 Investigations closed, singer Xhensila Myrtezaj’s case sent to trial
6 hours ago

Investigations closed, singer Xhensila Myrtezaj’s case sent to trial

3 Will the National Student Movement be declared a political force on November 28?
21 November 2026, 15:12

Will the National Student Movement be declared a political force on November 28?

4 Erion Veliaj dismisses two Municipality directors as Rama’s people
20 hours ago

Erion Veliaj dismisses two Municipality directors as Rama’s people

Koha Jone Logo

Daily, independent

  • Latest
  • News
  • Trending
  • WebTV
  • Region
  • World
  • Sports
  • Showbiz
  • Politics
  • Forum
  • Culture
  • Health
  • Editorial
  • Chronicle
  • Technology
  • Economy
  • Tourism
  • Social
  • Complaint in Koha Jonë
  • Contact
  • Privacy Policy
Download on the App Store Get it on Google Play

Newspaper "KOHA JONË" founded as an independent publication on 11 May 1991
Publisher: Nikoll LESI. Editorial office address: Rruga "Sami Frasheri", Pallatet e Aviacionit të Vjetër Nr. 2, TIRANA - ALBANIA

Site by
  • PUBLISHER & DIRECTOR: Nikoll LESI
  • EDITOR-IN-CHIEF: Daniel MUÇAKU
  • DEPUTY EDITOR-IN-CHIEF: Redjon SHTYLLA
  • BOARD: Elsa KAMBERI, KRYETARE
  • NIPT: J71425013C

© 2026 KOHA JONE. All rights reserved.